Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cell test aims to spot lung cancer sooner

NCT ID NCT03992183

Diagnosis Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a type of cell in the blood, called CAMLs, can help find early-stage lung cancer in people with suspicious lung nodules. Researchers planned to enroll 200 adults with nodules that had not yet been biopsied. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

May 2019

Finished

Nov 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will be drawn from pulmonary nodule clinics at the Fox Chase Cancer Center and the VAMC Philadelphia

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Referral for a pulmonary nodule that has not yet been biopsied and that meets the definition of an "indeterminate" nodules (i.e. 0.8-3.0 cm). * No prior diagnosis of lung cancer or other invasive malignancy within the past 5 years. * No history of rheumatologic disease. * Age \> 18 years. * Ability to understand and willingness to sign a written informed consent and HIPAA consent document Exclusion Criteria: * Patients with active, known or suspected autoimmune disease. * Prior diagnosis of lung cancer or other invasive malignancy within the past 5 years. * Uncontrolled intercurrent illness that would increase the risk of toxicity or limit compliance with study requirements. This includes but is not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the abnormal immune response that results from HIV disease (testing is not required). * Patients should be excluded if they are known to be positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (testing is not required). * Subjects with any history of interstitial lung disease or a history of \> or = to grade 2 radiation pneumonitis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary nodule, multiple are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Multiple Pulmonary Nodules pulmonary coin lesion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary nodule, multiple Pulmonary nodule, solitary

Contacts and locations

Locations

  • Corporal Michael J. Crescenz VA Medical Center

    Philadelphia, Pennsylvania, 19104, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.